483 related articles for article (PubMed ID: 25307456)
1. Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.).
Kreher S; Ochsenreither S; Trappe RU; Pabinger I; Bergmann F; Petrides PE; Koschmieder S; Matzdorff A; Tiede A; Griesshammer M; Riess H; ; ;
Ann Hematol; 2014 Dec; 93(12):1953-63. PubMed ID: 25307456
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH).
Appelmann I; Kreher S; Parmentier S; Wolf HH; Bisping G; Kirschner M; Bergmann F; Schilling K; Brümmendorf TH; Petrides PE; Tiede A; Matzdorff A; Griesshammer M; Riess H; Koschmieder S
Ann Hematol; 2016 Apr; 95(5):707-18. PubMed ID: 26916570
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of essential thrombocythemia].
Alvarez-Larrán A; Cervantes F; Besses C
Med Clin (Barc); 2013 Sep; 141(6):260-4. PubMed ID: 23490491
[TBL] [Abstract][Full Text] [Related]
4. Anticoagulation for COVID-19 Patients: A Bird's-Eye View.
Kreidieh F; Temraz S
Clin Appl Thromb Hemost; 2021; 27():10760296211039288. PubMed ID: 34595937
[TBL] [Abstract][Full Text] [Related]
5. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
[TBL] [Abstract][Full Text] [Related]
6. Management of the myeloproliferative disorders : distinguishing data from dogma.
Green AR; Vassiliou GS; Curtin N; Campbell PJ
Hematol J; 2004; 5 Suppl 3():S126-32. PubMed ID: 15190294
[No Abstract] [Full Text] [Related]
7. Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic.
Barbui T; De Stefano V
Curr Hematol Malig Rep; 2021 Oct; 16(5):455-463. PubMed ID: 34586561
[TBL] [Abstract][Full Text] [Related]
8. [Bridging: Perioperative management of chronic anticoagulation or antiplatelet therapy].
Nowak-Göttl U; Langer F; Limperger V; Mesters R; Trappe RU
Dtsch Med Wochenschr; 2014 Jun; 139(24):1301-6. PubMed ID: 24892468
[TBL] [Abstract][Full Text] [Related]
9. Thrombosis, thrombophilia, and thromboprophylaxis in pregnancy.
James AH; Brancazio LR; Ortel TL
Clin Adv Hematol Oncol; 2005 Mar; 3(3):187-97. PubMed ID: 16166990
[TBL] [Abstract][Full Text] [Related]
10. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders.
Wehmeier A; Südhoff T; Meierkord F
Semin Thromb Hemost; 1997; 23(4):391-402. PubMed ID: 9263357
[TBL] [Abstract][Full Text] [Related]
11. Management of venous thromboembolism in myeloproliferative neoplasms.
Barbui T; De Stefano V
Curr Opin Hematol; 2017 Mar; 24(2):108-114. PubMed ID: 27875375
[TBL] [Abstract][Full Text] [Related]
12. Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations.
Gangat N; Tefferi A
Am J Hematol; 2021 Mar; 96(3):354-366. PubMed ID: 33296529
[TBL] [Abstract][Full Text] [Related]
13. Anticoagulant-resistant thrombophilia in a patient with polycythemia vera: a case report.
Das S; Karachiwala H; Cherian SV; Garcha AS; Jasti S; Gajra A
Blood Coagul Fibrinolysis; 2011 Dec; 22(8):746-8. PubMed ID: 21885951
[TBL] [Abstract][Full Text] [Related]
14. Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms.
Huenerbein K; Sadjadian P; Becker T; Kolatzki V; Deventer E; Engelhardt C; Griesshammer M; Wille K
Ann Hematol; 2021 Aug; 100(8):2015-2022. PubMed ID: 33216197
[TBL] [Abstract][Full Text] [Related]
15. Prevention and treatment of venous thromboembolism in pregnancy.
James AH
Clin Obstet Gynecol; 2012 Sep; 55(3):774-87. PubMed ID: 22828110
[TBL] [Abstract][Full Text] [Related]
16. High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation.
Wille K; Sadjadian P; Becker T; Kolatzki V; Horstmann A; Fuchs C; Griesshammer M
Ann Hematol; 2019 Jan; 98(1):93-100. PubMed ID: 30155552
[TBL] [Abstract][Full Text] [Related]
17. [The PROMET study: Prophylaxis for venous thromboembolic disease in at-risk patients hospitalized in Algeria].
Guermaz R; Belhamidi S; Amarni A
J Mal Vasc; 2015 Jul; 40(4):240-7. PubMed ID: 26051861
[TBL] [Abstract][Full Text] [Related]
18. Pathogenesis and Management of Thrombotic Disease in Myeloproliferative Neoplasms.
Arachchillage DR; Laffan M
Semin Thromb Hemost; 2019 Sep; 45(6):604-611. PubMed ID: 31382304
[TBL] [Abstract][Full Text] [Related]
19. The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients.
Gonda DD; Fridley J; Ryan SL; Briceño V; Lam SK; Luerssen TG; Jea A
J Neurosurg Pediatr; 2015 Sep; 16(3):329-34. PubMed ID: 26067336
[TBL] [Abstract][Full Text] [Related]
20. European guidelines on perioperative venous thromboembolism prophylaxis: Chronic treatments with antiplatelet agents.
Llau JV; Kamphuisen P; Albaladejo P;
Eur J Anaesthesiol; 2018 Feb; 35(2):139-141. PubMed ID: 29112547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
